Osimertinib, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies.

Trial Profile

Osimertinib, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms TREM
  • Most Recent Events

    • 18 Oct 2017 Results (n=34) assessing Osimertinib in relapsed EGFR-mutated non-small cell lung cancer patients with brain metastases, presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Results evaluating Osimertinib in relapsed EGFR-mutated T790M-negative non-small cell lung cancer patients, presented at the 18th World Conference on Lung Cancer
    • 22 Jun 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top